贝伐珠单抗注射液联合常规含铂双药化疗方案治疗非小细胞肺癌的临床疗效及与患者VEGFR2基因多态性的关系  

Clinical Efficacy of Bevacizumab Injection Combined with Conventional Platinum-containing Dual-drug Chemotherapy in the Treatment of Non-small Cell Lung Cancer and its Relationship with VEGFR2 Gene Polymorphism

作　　者：徐卓冉 沈启良 XU Zhuoran;SHEN Qiliang(Department of Pharmacy,Henan Provincial People’s Hospital,Zhengzhou 450000,Henan,China;Department of Pharmacy,the First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450000,Henan,China)

机构地区：[1]河南省人民医院药学部,河南郑州450000 [2]河南省中医药大学第一附属医院药学部,河南郑州450000

出　　处：《中国药物滥用防治杂志》2024年第8期1499-1502,共4页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：河南省中医药科学研究专项重点课题(编号:2021ZY1049)。

摘　　要：目的:研究含铂双药化疗联合贝伐珠单抗治疗非小细胞肺癌(NSCLC)的临床疗效与血管内皮生长因子受体2(VEGFR2)基因多态性的关系。方法:选择2021年6月—2023年1月河南省人民医院108例NSCLC患者为研究对象,依据随机数字法分为对照组和试验组,每组54例。对照组给予含铂双药化疗方案,试验组在对照组基础上采用贝伐珠单抗,比较两组临床疗效、免疫功能指标,并分析试验组临床疗效与VEGFR2基因多态性的关系。结果:试验组临床总有效率为81.48%,高于对照组的61.11%(P<0.05);试验组化疗后CD8^(+)、CD4^(+)、CD3^(+)水平高于对照组(P<0.05)。CC型患者PFS、OS高于CT/TT型(P<0.05)。结论:贝伐珠单抗联合含铂双药化疗治疗NSCLC的效果显著,通过结合VEGF,阻断VEGF和VEGFR2等受体的相互作用,抑制肿瘤血管生成,改善预后。Objective:To study the relationship between the clinical efficacy of platinum-containing double-drug chemotherapy combined with bevacizumab in the treatment of non-small cell lung cancer(NSCLC)and vascular endothelial growth factor receptor 2(VEGFR2)gene polymorphism.Methods:A total of 108 patients with NSCLC in Henan Provincial People’s Hospital from June 2021 to January 2023 were selected as the research objects.According to the random number method,they were divided into control group and experimental group,with 54 patients in each group.The control group was treated with platinum-containing double-drug chemotherapy,and the experimental group was treated with bevacizumab on the basis of the control group.The clinical efficacy and immune function indexes of the two groups were compared,and the relationship between the clinical efficacy and VEGFR2 gene polymorphism in the experimental group was analyzed.Results:The total clinical effective rate of the experimental group was 81.48%,which was higher than 61.11%of the control group(P<0.05).The levels of CD8^(+),CD4^(+)and CD3^(+)in the experimental group were higher than those in the control group after chemotherapy(P<0.05).The PFS and OS of patients with CC type were higher than those of CT/TT type(P<0.05).Conclusion:Bevacizumab combined with platinum-containing double-drug chemotherapy is effective in the treatment of NSCLC.It inhibits tumor angiogenesis and improves prognosis by binding VEGF,blocking the interaction of receptors such as VEGF and VEGFR2.

关 键 词：非小细胞肺癌 贝伐珠单抗 血管内皮生长因子受体2 化疗 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]